Prognosis of Left Ventricular Non-Compaction
The prognosis of left ventricular non-compaction (LVNC) is highly variable and primarily determined by left ventricular systolic function rather than the degree of trabeculation itself—patients with preserved ejection fraction and no arrhythmias have excellent outcomes, while those with LV dysfunction face risks comparable to dilated cardiomyopathy. [@3,4,5,6,9,10@]
Clinical Spectrum and Risk Stratification
LVNC presents across a wide clinical spectrum. Many patients remain completely asymptomatic throughout life, while others develop heart failure, thromboembolism, arrhythmias, or sudden cardiac death [@3,4,5,6,9,10@]. The 2015 ESC Guidelines explicitly state that increased age, LV end-diastolic diameter at presentation, symptomatic heart failure, permanent or persistent atrial fibrillation, bundle branch block, and associated neuromuscular disease are reported predictors for increased mortality [@3,4,5,6,9,10@].
Key Prognostic Determinants
Left ventricular systolic dysfunction is the single most important prognostic factor. A systematic review and meta-analysis found that LV ejection fraction—not the extent of trabeculation—had the most significant influence on adverse outcomes 1. Patients with LVNC carry cardiovascular risks similar to dilated cardiomyopathy patients when matched for ejection fraction 1.
The most recent prospective multicenter CMR study (2016) demonstrated that LV dilation and late gadolinium enhancement (LGE) are the strongest CMR predictors of cardiac events, while the degree of trabeculation itself had no prognostic impact 2. Notably, no cardiac events occurred in patients without dilated cardiomyopathy features and/or LGE 2.
Subtype-Specific Outcomes
A critical distinction exists between LVNC subtypes:
- Isolated LVNC with preserved systolic function: Excellent prognosis with minimal risk of cardiovascular death or severe ventricular arrhythmias [@16,17@]
- Dilated LVNC: Significantly worse outcomes with adjusted hazard ratio of 4.43 compared to isolated LVNC 3
Specific Risk Profiles
Arrhythmic Risk
Ventricular arrhythmias occur at a rate of 2.17 per 100 person-years 1. The most recent 2025 study identified that frequent premature ventricular contractions (>500/day), non-sustained ventricular tachycardia, and low QRS voltage predict life-threatening arrhythmic events and ICD interventions 4. Sustained ventricular tachycardia is associated with PVCs, low QRS voltage, and atrioventricular block 4.
Thromboembolic Risk
Thromboembolism occurs at 1.54 per 100 person-years 1. The 2025 study found that NYHA class ≥3, right ventricular end-diastolic diameter ≥3 cm, right atrial volume ≥67 mL, LV end-diastolic diameter ≥6.3 cm, and velocity time integral ≤11.2 cm predict thromboembolic events 4. The risk is similar between LVNC and dilated cardiomyopathy patients 1.
Mortality and Heart Failure
Cardiovascular mortality occurs at 1.92 per 100 person-years, with all-cause mortality at 2.16 per 100 person-years 1. Heart failure hospitalization occurs at 3.53 per 100 person-years—higher than in dilated cardiomyopathy patients 1.
Fatal outcomes are specifically associated with:
- E/A ratio >1.9
- LV ejection fraction <35%
- NYHA class ≥3
- Ventricular tachycardia
- Superimposed myocarditis 4
Management Implications from ESC Guidelines
The 2015 ESC Guidelines state that ICD decisions should be guided by the severity of LV systolic dysfunction and presence of sustained ventricular arrhythmias using the same criteria as dilated cardiomyopathy [@3,4,5,6,9,10@]. The guidelines emphasize that there are few data to suggest that LV non-compaction by itself is an indication for an ICD [@3,4,5,6,9,10@].
Common Pitfalls
The major clinical pitfall is over-diagnosing LVNC based solely on trabeculation patterns. Up to 20% of individuals without cardiomyopathy meet morphological criteria, and trabeculation can be physiological in athletes and pregnancy [@18,19,20@]. The 2026 reviews emphasize that prognosis is determined primarily by ventricular function, myocardial substrate, and arrhythmic burden rather than by the extent of trabeculation itself 5.
Anticoagulation should be used in all patients with atrial fibrillation, as recommended by ESC guidelines for restrictive cardiomyopathy management principles that apply to LVNC [@3,4,5,6,9,10@].